Market Eyes LiveVertex Pharmaceuticals Inc (VRTX) Stock Rating & Analysis
MELANY's data-driven read on Vertex Pharmaceuticals Inc · Pharmaceutical Preparations.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for serious diseases. Its main products are the cystic fibrosis therapies Kalydeco, Orkambi, Symdeko, Trikafta/Kaftrio, and Alyftrek, where its treatments remain the global standard of care. It has broadened its portfolio with Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid medication for moderate-to-severe acute pain in adults.
Why VRTX scores 60/100
MELANY scores Vertex Pharmaceuticals Inc 60/100 by weighing eight factors. Here is how VRTX breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
- Gross margin 55%
- ROE 24%
Direction and relative strength of the recent share-price trend.
- Price +10.7% above 50-day MA
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for VRTX
- Performance partly driven by Biotech (GLP-1 + innovation cluster), rotation away from this theme would hurt
- Trading near 52-week high, limited upside without new positive catalyst
Sector and theme context
Vertex Pharmaceuticals Inc sits in the Biotech (GLP-1 + innovation cluster) theme, which MELANY currently rates 76/100 for strength. Theme strength feeds VRTX's momentum and catalyst factors above.
VRTX trade plan (members only)
MELANY has a full position plan for Vertex Pharmaceuticals Inc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates VRTX
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Vertex Pharmaceuticals Inc's 60/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about VRTX
Is Vertex Pharmaceuticals Inc (VRTX) a buy?
As of 2026-08-21, MELANY rated Vertex Pharmaceuticals Inc Runner! with a composite score of 60/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Vertex Pharmaceuticals Inc's MELANY score?
Vertex Pharmaceuticals Inc (VRTX) has a MELANY composite score of 60/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the VRTX stock rating calculated?
MELANY scores VRTX from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Vertex Pharmaceuticals Inc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Vertex Pharmaceuticals Inc (VRTX) Runner! with a composite of 60/100 as of 2026-08-21. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the VRTX stock price forecast?
MELANY does not publish price targets or forecasts for VRTX. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 60/100 across eight factors for Vertex Pharmaceuticals Inc, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is VRTX stock overvalued or undervalued?
MELANY's valuation factor currently reads 36/100 for Vertex Pharmaceuticals Inc, where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives VRTX's read.
What price should I buy VRTX at?
Rather than chasing the current price, MELANY computes a smart entry zone for VRTX: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying VRTX stock?
The top risks MELANY currently flags for Vertex Pharmaceuticals Inc: Performance partly driven by Biotech (GLP-1 + innovation cluster), rotation away from this theme would hurt; Trading near 52-week high, limited upside without new positive catalyst. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Vertex Pharmaceuticals Inc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 83/100 for Vertex Pharmaceuticals Inc, and earnings track record, at 58/100. The 60/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will VRTX stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 76/100 for VRTX right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this VRTX rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-21. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores VRTX continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
VRTX's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.